RxDoctor Payments Data

Mark Bej, MD

Neurology · Sheffield Village, OHNPI 1427040914

Payments from drug & device makers

$27,982in general payments, 2019–2025

Across 924 payments — averaging $30.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$4K
  • Jazz Pharmaceuticals Inc.$2K
  • AbbVie$2K
  • Livanova USA, Inc.$2K
  • UCB, Inc.$2K
  • SK Life Science, Inc.$2K
  • plus $15K from 54 others

What the payments were for

  • Consulting fees$2,6509%
  • Travel & lodging$1,7996%
  • Food & beverage$23,40784%
  • Education$1270%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Teva Pharmaceuticals USA, Inc.50$4,444
Jazz Pharmaceuticals Inc.60$1,853
AbbVie(2 entities)79$1,829
Livanova USA, Inc.16$1,773
UCB, Inc.59$1,538
SK Life Science, Inc.85$1,501
Lilly USA, LLC60$1,250
Lundbeck LLC55$1,068
Amgen(2 entities)40$996
Eisai Inc.36$944
Biohaven Pharmaceuticals, Inc.17$774
Sanofi16$717
Harmony Biosciences LLC22$700
E.r. Squibb & Sons, L.L.C.7$696
Neurelis, Inc.24$618
EMD Serono, Inc.15$555
Axsome Therapeutics, Inc.17$504
Neurocrine Biosciences, Inc.23$445
Novartis29$420
Pfizer22$373
Biogen14$339
Greenwich Biosciences, Inc.11$336
AstraZeneca8$315
Genentech USA, Inc.16$310
Avadel CNS Pharmaceuticals, LLC6$305
Bristol Myers Squibb10$293
Mallinckrodt Hospital Products Inc.3$239
Biohaven Pharmaceutical Holding Company Ltd.17$231
Kyowa Kirin, Inc.7$209
Impel Pharmaceuticals Inc.2$190
Neuropace, Inc.1$165
Merck9$159
Ironshore Pharmaceuticals Inc.4$155
Grifols USA, LLC6$139
Impel Pharmaceuticals LLC8$127
Sunovion Pharmaceuticals Inc.1$125
Supernus Pharmaceuticals, Inc.6$121
Aucta Pharmaceuticals, Inc.5$103
Xeris Pharmaceuticals, Inc.5$101
Amneal Pharmaceuticals LLC5$93
Acadia Pharmaceuticals Inc3$84
Johnson & Johnson4$72
Otsuka America Pharmaceutical, Inc.3$68
Arbor Pharmaceuticals, Inc.4$66
Cala Health, Inc.3$62
Abbott3$61
MDD US Operations, LLC3$54
Corium, LLC2$50
Springworks Therapeutics, Inc.3$47
Argenx US, Inc.2$43
GE HealthCare3$42
Takeda Pharmaceuticals U.S.A., Inc.2$41
Avanir Pharmaceuticals, Inc.2$36
Ceribell, Inc.1$28
CSL Behring1$23
TG Therapeutics, Inc.1$22
Avion Pharmaceuticals1$21
ANI Pharmaceuticals, Inc.1$18
Catalyst Pharmaceuticals, Inc.1$17
Amylyx Pharmaceuticals, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,982 in reported general payments places this provider in the 70th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio

Medicare billing

Part B allowed, 2024
$155,498
Medicare patients
486
Services billed
3,229

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SkyclarysOmaveloxolone12$388,478
BriviactBrivaracetam172$306,249
EpidiolexCannabidiol (Cbd)59$177,182
Lamictal XrLamotrigine17$103,636
IngrezzaValbenazine Tosylate12$101,274
QuliptaAtogepant74$79,146
Nurtec OdtRimegepant Sulfate55$78,868
TopamaxTopiramate25$78,070
XcopriCenobamate62$77,741
CopaxoneGlatiramer Acetate13$75,816
Emgality PenGalcanezumab-Gnlm75$71,845
Aimovig AutoinjectorErenumab-Aooe60$58,537
Lamotrigine ErLamotrigine77$39,509
FycompaPerampanel22$37,818
NuedextaDextromethorphan Hbr/Quinidine18$25,022

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenSkyclarys$339$388,47812 claims
UCB, Inc.Briviact, Nayzilam$1,538$317,414187 claims
Neurocrine Biosciences, Inc.Ingrezza$445$101,27412 claims
AbbVieQulipta$1,829$79,14674 claims
PfizerNurtec Odt$373$78,86855 claims
SK Life Science, Inc.Xcopri$1,501$77,74162 claims
Teva Pharmaceuticals USA, Inc.Copaxone$4,444$75,81613 claims
Eisai Inc.Fycompa$944$37,81822 claims
Avanir Pharmaceuticals, Inc.Nuedexta$36$25,02218 claims
NovartisExelon$420$13,51515 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$41$4,26811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 702 neurology providers in Ohio.

Other neurology in Sheffield Village

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →